A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer - Concepedia

Concepedia

Publication | Closed Access

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

197

Citations

40

References

2005

Year

Kathy D. Miller, José Trigo, Catherine Wheeler, Alan Barge, Jacqui Rowbottom, George W. Sledge, José Baselga

Clinical Cancer Research

Abstract

ZD6474 monotherapy was generally well tolerated but had limited monotherapy activity in patients with refractory metastatic breast cancer.

References

	Year	Citations

Page 1